



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7


mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

6PGD-IN-1

Cat. No.:	HY-N7850
CAS No.:	5539-66-2
Molecular Formula:	C ₁₅ H ₁₀ O ₄
Molecular Weight:	254.24
Target:	Others
Pathway:	Others
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	6PGD-IN-1 (compound S3) is an inhibitor of 6-phosphogluconate dehydrogenase (6PGD). IC ₅₀ and K _d the value of 17.8μM and 17.1 μM respectively. 6PGD-IN-1 has antitumor activity ^[1] .								
In Vitro	6PGD-IN-1 (10-40 μM, 24-72 h) inhibits the cell viability of H1299 and K562 ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.								
In Vivo	6PGD-IN-1 (20 mg/kg/day intraperitoneally for 4 weeks) reduces tumor growth and volume in xenografted nude mice injected subcutaneously with H1299 cells ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.								
	<table border="1"> <tr> <td>Animal Model:</td> <td>H1299-xenograft mice^[1]</td> </tr> <tr> <td>Dosage:</td> <td>20 mg/kg</td> </tr> <tr> <td>Administration:</td> <td>i.p.</td> </tr> <tr> <td>Result:</td> <td>Decreased 6PGD activity and reduced Ki-67 expression.</td> </tr> </table>	Animal Model:	H1299-xenograft mice ^[1]	Dosage:	20 mg/kg	Administration:	i.p.	Result:	Decreased 6PGD activity and reduced Ki-67 expression.
Animal Model:	H1299-xenograft mice ^[1]								
Dosage:	20 mg/kg								
Administration:	i.p.								
Result:	Decreased 6PGD activity and reduced Ki-67 expression.								

REFERENCES

[1]. Lin R, et al. 6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling. Nat Cell Biol. 2015 Nov;17(11):1484-96.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA